Question 1

Has Jay Rubin received payments from drug or device companies?

Accepted Answer

Yes. Drug and device makers reported $6,788,594 in general payments to Jay Rubin across 966 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Question 2

Does a payment mean Jay Rubin did something wrong?

Accepted Answer

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Question 3

Where does this information about Jay Rubin come from?

Accepted Answer

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Company	Payments	Total
Eisai Inc.	878	$2,904,836
Biogen	10	$1,993,417
Novartis	4	$1,227,861
Eli Lilly	17	$456,581
Boehringer Ingelheim	2	$200,921
Boehringer Ingelheim RCV GmbH & Co KG	13	$3,457
Acadia Pharmaceuticals Inc	6	$721
Medtronic	3	$199
SK Life Science, Inc.	1	$123
AstraZeneca	3	$77
Lilly USA, LLC	4	$67
MDD US Operations, LLC	3	$55
Acorda Therapeutics, Inc	2	$48
Grifols USA, LLC	2	$38
Jazz Pharmaceuticals Inc.	2	$31
Sunovion Pharmaceuticals Inc.	3	$27
Alnylam Pharmaceuticals Inc.	1	$26
GE HealthCare	1	$25
Avanir Pharmaceuticals, Inc.	1	$20
Amgen	1	$18
UCB, Inc.	1	$17
Si-bone, Inc.	1	$15
Nevro Corp.	1	$14
Innovation Technologies Inc	6	$0

Jay Rubin

Payments from drug & device makers

Who reported the general payments

How this compares

Other neuromusculoskeletal medicine & omm in Ocala